洞察
关于 AI 驱动生命科学探索的研究分析、行业视角与深度解析
精选
How an output-driven perspective can help researchers select graph-based AI models for drug-target interaction research, with a closer look at DTIGN and LigoSPACE.
洞察
SuperWater, a generative AI framework developed to predict water molecule positions around biomolecular complexes, offers a new approach to this longstanding computational challenge.
洞察
In this second edition of Vecura Biotech Insiders, we highlight a workflow shared with the Vecura team by Tony 阮进成 during the support process.
洞察
In this Vecura Biotech Insiders feature, we explore a user-shared workflow for building a copper-tagged human tyrosinase model from AlphaFold, benchmarking it against mushroom tyrosinase, and preparing it for structure-based docking.
洞察
A walkthrough of how to build an atomic model from a cryo-EM density map
洞察
How the Vecura platform runs Boltz-2.1 through the API as the structure-validation engine inside a multi-model design pipeline, folding nine designed sequences with ten sampled models each and turning per-structure confidence into a triage signal for what to carry forward.
洞察
A Vecura workflow, chaining generative small-molecule design, structure-based docking, ADMET prediction and toxicophore-constrained redesign against the angiotensin II type 1 receptor. What the platform surfaced was not a drug candidate but something more useful, a quantified account of the potency-safety tradeoff that governs this chemotype.
洞察
A community workflow example using AutoDock Vina and GROMACS on Vecura
洞察
A proposed computational pipeline for identifying small-molecule binders at the SOD1 dimer interface
洞察
A walkthrough of how modern protein design models behave when pointed at a hard, conserved kinase pocket, and what the output does and does not tell us.
洞察
AlphaFold, developed by DeepMind, is an AI system that predicts protein structures from amino acid sequences with high accuracy using deep learning, significantly advancing protein folding research. Its impact spans drug discovery, disease research, and synthetic biology, and its open-access nature has fostered global scientific collaboration—making it a landmark example of AI's potential to tackle complex biological challenges.
.png)
洞察
Covalent inhibitors occupy a unique space in drug discovery. By forming irreversible interactions with target residues, they can achieve sustained target engagement and prolonged pharmacological activity beyond what is often possible with non-covalent ligands. However, optimizing covalent scaffolds presents a distinct challenge: favorable binding affinity alone is insufficient. Productive activity depends on precise geometric alignment between the reactive warhead and the target nucleophile.
